Top Markets
#1 ORDI ORDI +75.07%
#2 tomiNet tomiNet +42.74%
#3 1000SATS (Ordinals) 1000SATS (Ordinals) +37.39%
#4 SATS (Ordinals) SATS (Ordinals) +36.77%
#5 pippin pippin +33.93%
#6 Axelar Axelar +33.55%
#7 Swarms Swarms +25.58%
#8 Bio Protocol Bio Protocol +23.17%
#9 Walrus Walrus +20.25%
#10 Zerebro Zerebro +20.22%
Coin of the day
ORDI ORDI
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang in aandelen #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aandeelprijs
$0.00047446
Marktkapitalisatie
$82.80
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Categorie

Healthcare
Aandelsplitsingen voor Neovacs S.A. (ALNEV)
Het aandeel Neovacs S.A. (symbool: ALNEV) heeft in totaal 6 splitsingen ondergaan.
De meest recente splitsing vond plaats op Jul 18, 2025.
Eén aandeel ALNEV dat vóór Feb 01, 2022 werd gekocht, staat nu gelijk aan 1.5625E-23 aandelen ALNEV.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
2025-07-18 1:1000 x0.001 x1.5625E-23
2024-12-05 1:10000 x0.0001 x1.5625E-20
2024-02-06 1:10000 x0.0001 x1.5625E-16
2023-06-05 1:8000 x0.000125 x1.5625E-12
2023-06-02 1:8000 x0.000125 x1.25E-8
2022-02-01 1:10000 x0.0001 x0.0001
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5 x199
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 0 -
US
UCB SA UCB SA
UCB SA
UCB.BR
 0 -
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL